National Institute of Mental Health; Notice of Closed Meetings, 26059-26060 [2021-10026]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 90 / Wednesday, May 12, 2021 / Notices
Dated: May 5, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2021–09980 Filed 5–11–21; 8:45 am]
Department of Health and Human
Services, Room L616, Switzer Building,
330 C. St. SW, Washington, DC 20024.
Phone: 202–746–1512; Email: CARB@
hhs.gov.
BILLING CODE 4164–01–P
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Presidential Advisory
Council on Combating AntibioticResistant Bacteria
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that a meeting is scheduled to be held
for the Presidential Advisory Council on
Combating Antibiotic-Resistant Bacteria
(PACCARB). The meeting will be open
to the public via WebEx and
teleconference; a pre-registered public
comment session will be held during
the meeting. Pre-registration is required
for members of the public who wish to
attend the meeting via WebEx/
teleconference. Individuals who wish to
send in their written public comment
should send an email to CARB@hhs.gov.
Registration information is available on
the website https://www.hhs.gov/paccarb
and must be completed by June 25,
2021. Additional information about
registering for the meeting and
providing public comment can be
obtained at https://www.hhs.gov/paccarb
on the Meetings page.
DATES: The meeting is scheduled to be
held on June 29, 2021, from 10:00 a.m.
to 3:00 p.m. and June 30, 2021, from
10:00 a.m. to 3:00 p.m. ET (times are
tentative and subject to change). The
confirmed times and agenda items for
the meeting will be posted on the
website for the PACCARB at https://
www.hhs.gov/paccarb when this
information becomes available. Preregistration for attending the meeting is
strongly suggested and should be
completed no later than June 25, 2021.
ADDRESSES: Instructions regarding
attending this meeting virtually will be
posted one week prior to the meeting at:
https://www.hhs.gov/paccarb.
FOR FURTHER INFORMATION CONTACT:
Jomana Musmar, M.S., Ph.D.,
Designated Federal Officer, Presidential
Advisory Council on Combating
Antibiotic-Resistant Bacteria, Office of
the Assistant Secretary for Health, U.S.
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:58 May 11, 2021
Jkt 253001
The
Presidential Advisory Council on
Combating Antibiotic-Resistant Bacteria
(PACCARB), established by Executive
Order 13676, is continued by Section
505 of Public Law 116–22, the
Pandemic and All-Hazards
Preparedness and Advancing Innovation
Act of 2019 (PAHPAIA). Activities and
duties of the Advisory Council are
governed by the provisions of the
Federal Advisory Committee Act
(FACA), Public Law 92–463, as
amended (5 U.S.C. App.), which sets
forth standards for the formation and
use of federal advisory committees.
The PACCARB shall advise and
provide information and
recommendations to the Secretary
regarding programs and policies
intended to reduce or combat antibioticresistant bacteria that may present a
public health threat and improve
capabilities to prevent, diagnose,
mitigate, or treat such resistance. The
PACCARB shall function solely for
advisory purposes.
Such advice, information, and
recommendations may be related to
improving: The effectiveness of
antibiotics; research and advanced
research on, and the development of,
improved and innovative methods for
combating or reducing antibiotic
resistance, including new treatments,
rapid point-of-care diagnostics,
alternatives to antibiotics, including
alternatives to animal antibiotics, and
antimicrobial stewardship activities;
surveillance of antibiotic-resistant
bacterial infections, including publicly
available and up-to-date information on
resistance to antibiotics; education for
health care providers and the public
with respect to up-to-date information
on antibiotic resistance and ways to
reduce or combat such resistance to
antibiotics related to humans and
animals; methods to prevent or reduce
the transmission of antibiotic-resistant
bacterial infections; including
stewardship programs; and coordination
with respect to international efforts in
order to inform and advance the United
States capabilities to combat antibiotic
resistance.
The June 29–30, 2021, public meeting
will be dedicated to the council’s
deliberation and vote on two reports to
transmit to the Secretary of Health and
Human Services, the first from the
Disparities in Antibiotics Access and
Use Working Group, and the second
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
26059
from the Working Group on
Antimicrobial Resistance (AMR) in
Inter-Professional Education. The
remainder of the two-day public
meeting will include an update on the
status of the antibiotic development
pipeline and an open council discussion
on provocative questions in AMR (no
recommendations will be made), in
addition to presentations from subject
matter experts on Operationalizing One
Health and the Environmental
Dimensions of AMR. The meeting
agenda will be posted on the PACCARB
website at https://www.hhs.gov/paccarb
when it has been finalized. All agenda
items are tentative and subject to
change.
Instructions regarding attending this
meeting virtually will be posted one
week prior to the meeting at: https://
www.hhs.gov/paccarb.
Members of the public will have the
opportunity to provide comments live
during the meeting via conference line
by pre-registering online at https://
www.hhs.gov/paccarb. There will be
two separate sessions available for
public comment: An Innovation
Spotlight will be held on June 29th
where companies and/or organizations
involved in combating antibiotic
resistance have an opportunity to
present their work to members of the
Advisory Council; and on June 30th,
where all members of the general public
are welcome to provide oral comment
during this separate session. Preregistration is required for participation
in these sessions with limited spots
available. Further information about
these two sessions can be found online
at https://www.hhs.gov/paccarb. Written
public comments can also be emailed to
CARB@hhs.gov by midnight June 25,
2021 and should be limited to no more
than one page. All public comments
received prior to June 25, 2021, will be
provided to Advisory Council members.
Dated: April 30, 2021.
Jomana F. Musmar,
Designated Federal Officer, Presidential
Advisory Council on Combating AntibioticResistant Bacteria, Office of the Assistant
Secretary for Health.
[FR Doc. 2021–10014 Filed 5–11–21; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\12MYN1.SGM
12MYN1
26060
Federal Register / Vol. 86, No. 90 / Wednesday, May 12, 2021 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Pilot
Effectiveness Trials for Treatment,
Prevention, and Services Interventions (R34).
Date: June 8, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Serena Chu, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH Neuroscience Center,
6001 Executive Blvd., Room 6000, MSC 9606,
Bethesda, MD 20852, 301–500–5829,
serena.chu@nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Device Development.
Date: June 9, 2021.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Nicholas Gaiano, Ph.D.,
Review Branch Chief, Division of Extramural
Activities, National Institute of Mental
Health, NIH, Neuroscience Center/Room
6150/MSC 9606, 6001 Executive Boulevard,
Bethesda, MD 20892–9606, 301–443–2742,
nick.gaiano@nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Mood
Disorders in People Living with HIV:
Mechanisms and Pathways (R01 & R21).
Date: June 9, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Rebecca Steiner Garcia,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6149, MSC 9608,
Bethesda, MD 20892–9608, 301–443–4525,
steinerr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
VerDate Sep<11>2014
17:58 May 11, 2021
Jkt 253001
Dated: May 7, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–10026 Filed 5–11–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Center for
Advancing Translational Sciences
Advisory Council.
The meeting will be open to the
public as indicated below. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://videocast.
nih.gov). Individuals who plan to attend
and need special assistance, such as
sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Advisory
Council.
Date: June 10–11, 2021.
Closed: June 10, 2021, 11:00 a.m. to 12:30
p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, One Democracy Plaza, 6701
Democracy Boulevard, Room 987/987,
Bethesda, MD 20892 (Virtual Meeting).
Open: June 10, 2021, 1:00 p.m. to 4:00 p.m.
Agenda: Report from the Institute Director
and other staff.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, One Democracy Plaza, 6701
Democracy Boulevard, Room 987/987,
Bethesda, MD 20892 (Virtual Meeting).
Open: June 11, 2021, 1:00 p.m. to 5:00 p.m.
Agenda: To view and discuss Clearance of
Concepts.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, One Democracy Plaza, 6701
Democracy Boulevard, Room 987/987,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Anna L. Ramsey-Ewing,
Ph.D., Executive Secretary, National Center
for Advancing Translational Sciences,
National Institutes of Health, One Democracy
Plaza, 6701 Democracy Boulevard, Room
1072, Bethesda, MD 20892, 301–435–0809,
anna.ramseyewing@nih.gov.
Attendees and interested parties may
submit questions and comments through
written Q&A during the meeting, and for 15
days after the meeting, to
NCATSCouncilInput@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice no later than 15 days after the
meeting. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: May 7, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–10021 Filed 5–11–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer Institute
Clinical Trials and Translational
Research Advisory Committee.
The meeting will be held as a virtual
meeting and is open to the public.
Individuals who plan to view the virtual
meeting and need special assistance or
other reasonable accommodations to
view the meeting, should notify the
Contact Person listed below in advance
of the meeting. The meeting will be
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov).
Name of Committee: National Cancer
Institute Clinical Trials and Translational
Research Advisory Committee (CTAC) Ad
hoc Translational Research Strategy
Subcommittee.
Date: June 17, 2021.
Time: 11:00 a.m. to 12:00 p.m.
E:\FR\FM\12MYN1.SGM
12MYN1
]]>Agencies
[Federal Register Volume 86, Number 90 (Wednesday, May 12, 2021)]
[Notices]
[Pages 26059-26060]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-10026]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
[[Page 26060]]
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Pilot Effectiveness Trials for Treatment,
Prevention, and Services Interventions (R34).
Date: June 8, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Serena Chu, Ph.D., Scientific Review Officer,
Division of Extramural Activities, National Institute of Mental
Health, NIH Neuroscience Center, 6001 Executive Blvd., Room 6000,
MSC 9606, Bethesda, MD 20852, 301-500-5829, [email protected].
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Device Development.
Date: June 9, 2021.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Nicholas Gaiano, Ph.D., Review Branch Chief,
Division of Extramural Activities, National Institute of Mental
Health, NIH, Neuroscience Center/Room 6150/MSC 9606, 6001 Executive
Boulevard, Bethesda, MD 20892-9606, 301-443-2742,
[email protected].
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Mood Disorders in People Living with HIV: Mechanisms
and Pathways (R01 & R21).
Date: June 9, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Rebecca Steiner Garcia, Ph.D., Scientific Review
Officer, Division of Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room
6149, MSC 9608, Bethesda, MD 20892-9608, 301-443-4525,
[email protected].
(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental
Health Research Grants, National Institutes of Health, HHS)
Dated: May 7, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-10026 Filed 5-11-21; 8:45 am]
BILLING CODE 4140-01-P
